Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 13Esophageal Squamous Cell Carcinoma 7Rectal Neoplasms 4Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Lung Neoplasms 2Head and Neck Neoplasms 2HER2-positive Breast Cancer 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Turcot syndrome 1Testicular Neoplasms 1Squamous Cell Carcinoma of External Auditory Canal 1Seminoma 1Recurrence 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma (PDAC) 1Neoplastic Cells, Circulating 1Neoplasm Metastasis 1Neoadjuvant Therapy 1

Interventions

Taxes 1Neoadjuvant Therapy 1Gemcitabine 1FAPI-46 1Endosonography 1Blood Specimen Collection 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Pancreatic Ductal Adenocarcinoma (PDAC) × Neoadjuvant Therapy × Clear all
NCT04990609 2025-05-21

EUS-RFA PANCARDINAL-1 Trial

The University of Texas Health Science Center, Houston

Phase 2 Recruiting
60 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma (PDAC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡